Skip to content
Medical Health Aged Care

Former Facebook CEO (ANZ) Stephen Scheeler Announced as Keynote Speaker for Better Outcomes

AlayaCare 2 mins read

SYDNEY, AUSTRALIA / ACCESSWIRE / June 17, 2024 / AlayaCare, a leading Home and Residential Care software provider, today announces Stephen Scheeler - former CEO of Facebook ANZ, renowned business leader, and digital innovation expert - as the keynote speaker at Better Outcomes 2024. Better Outcomes is AlayaCare's flagship user conference that will be held on 3 September in Sydney.

Scheeler brings vast experience as a leader who drove Facebook's unprecedented rise in Australia and New Zealand, and as a strategic advisor to major corporations on digital disruption and the future of technology. Scheeler's insights, demonstrated by his contributions to TEDx, The Wall Street Journal, Forbes, and The Australian Financial Review, will provide valuable insights to attendees looking to prioritise innovation and transformation in the digital age.

Following a successful year in 2023, Better Outcomes returns in 2024 to provide professionals in the aged and disability industry with an unparalleled opportunity to learn from leading industry experts about the latest advancements in healthcare technology. Better Outcomes melds innovation and practical application, empowering attendees to implement leading practices, forge lasting industry relationships, and be at the forefront of technological advancement in their sector.

"We are thrilled to have Stephen Scheeler speaking at Better Outcomes this year," says Annette Hili, General Manager AlayaCare ANZ. "In a sector that is constantly evolving, Stephen's insights into technological transformation and innovation will be incredibly valuable to our attendees. We look forward to the inspiration and practical knowledge he will share, helping our community achieve better outcomes in care delivery."

Learn more about Better Outcomes and register here: https://alayacare.com/en-au/better-outcomes-2024/

For more information, please contact:

Bel Bennett
Director Marketing ANZ
[email protected]

About AlayaCare

AlayaCare is a leading technology provider for the aged and disability sectors, revolutionising care delivery through AI-based software. Our platform, supported by a dedicated local team, streamlines operations, offers real-time data insights, enhances personalised care, and enables seamless customisation without vendor support. With a $50 million annual investment in research and AI-driven solutions, AlayaCare is at the forefront of driving innovation in the care community. Visit alayacare.com.au to learn about our transformative, world-class technology that's tailor-made for aged and disability providers.

SOURCE: AlayaCare



View the original press release on accesswire.com

More from this category

  • Community, Medical Health Aged Care
  • 08/12/2025
  • 04:15
Save Our Sons Duchenne Foundation

Global Clinical Experts Gather in Sydney to Advance Adult Duchenne Muscular Dystrophy Care

Key Facts: Life expectancy for Australians living with DMD have increased from 18 for those borne before 1970, to around 30 today. As adult care remains fragmented and inconsistent between hospitals and States, the Symposium will develop global multi-disciplinary care recommendations.MEDIA RELEASE A world-first International Symposium dedicated toimproving multi-disciplinary clinical care for adults living with Duchenne muscular dystrophy (DMD) will take place in Sydney over the next three days. Hosted by the Save Our Sons Duchenne Foundation, the invitation-only event will bring together more than 35 of the world’s leading clinicians and researchers to develop the first multidisciplinary, global best-practice…

  • Contains:
  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

  • Medical Health Aged Care
  • 06/12/2025
  • 02:11
Arthur D. Little

Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation

NEW YORK–BUSINESS WIRE– Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design,…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.